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license (http://creativein familiarity is expected in very early stages of Alzheimer’s disease (AD). The apolipoprotein E
(APOE) ε4 allele is a major risk factor for AD. Here, we investigated the effect of the APOE ε4 status
on familiarity in cognitively normal aging individuals.
Methods: Eighty-one individuals aged between 55 and 80 years, 21 carriers and 60 noncarriers, were
used in these analyses. A cognitive evaluation was performed on all participants to document the
absence of objective cognitive deficits. The effect of APOE ε4 status on familiarity was tested using
independent sample t test and an analysis of covariance controlling for age, gender, and education.
Results: The groups did not differ in term of age, education, and male/female ratio. APOE ε4 carriers
showed a significant reduction in familiarity. No other cognitive deficit was observed in the group of
ε4 carriers, relative to noncarriers.
Discussion: APOE ε4 is associated with a reduction in familiarity in the absence of other cognitive
deficits. These results suggest that performance in familiarity could represent an early cognitive
marker for individuals at risk of AD.
 2016 The Authors. Published by Elsevier Inc. on behalf of Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Keywords: Aging; Apolipoprotein E; Familiarity; Recollection; Cognitive marker; Alzheimer’s disease1. Introduction
Owing to the aging of the population, a worldwide phe-
nomenon, the burden of Alzheimer’s disease (AD) is ex-
pected to increase dramatically over the next decades [1].
Because of its insidious progression, AD is often only de-
tected at a relatively advanced stage of neurodegeneration,
when clinical manifestations and functional impairments
are observable. Detecting AD at an earlier stage could
contribute to the development of new interventions (pharma-
ceutical or not) to slow or halt the progression of the disease.
The development of new cognitive tests sensitive to early
cognitive changes associated with impending AD could
contribute to this objective.thor. Tel.: 11-514-766-2010; Fax: 514-888-4050.
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commons.org/licenses/by-nc-nd/4.0/).AD is a progressive and neurodegenerative condition that
develops over several decades [2]. In the first stages of AD,
also known as transentorhinal stages, the entorhinal and peri-
rhinal cortices (EC/PC) are targeted by neurofibrillary tan-
gles [3]. Histopathologic studies have demonstrated
important neuronal loss in the EC at the earliest stages of de-
mentia. A study by Gomez-Isla et al. [4] revealed that indi-
viduals with a clinical dementia rating scale score of 0.5
presented 32% less neurons in the EC relative to aged-
matched controls. Magnetic resonance imaging volumetric
studies also reported significant EC volume reduction in in-
dividuals with mild AD, with one study revealing a volume
loss as high as 40% in this region for patients with AD [5].
The functionality of the EC/PC region is also altered in the
course of pathologic aging. A longitudinal positron emission
tomography study showed that glucose metabolism in the
EC accurately predicted cognitive decline over a period ofer’s Association. This is an open access article under the CC BY-NC-ND
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and frontal lobes, the EC was found to be to the most accu-
rate predictor of cognitive changes over time. These findings
demonstrate that the EC/PC region is very sensitive to early
pathologic alterations associated with AD. Thus, detecting
an impaired functionality of these regions could allow early
and specific identification of subjects with preclinical AD.
However, this is hindered by the fact that transentorhinal
stages of AD, also referred to as “silent stages,” are believed
to occur before observable clinical manifestations [3].
The functional role of the EC/PC has been extensively
studied over the past decades, but the vast majority of studies
investigating its function have been performed in animals.
Hence, its role in human cognition continues to be a matter
of debate. Recent evidence suggests that the EC/PC is asso-
ciated with familiarity [7,8]. According to dual-process
models, familiarity and recollection are two distinct and in-
dependent processes involved in the recognition of previ-
ously seen material. Recollection can be defined as a
recognition episode accompanied by retrieval of contextual
details associated with the encoding sequence. In contrast,
familiarity is perceived as a recognition based on a feeling
of “knowledge” that a stimulus has previously been encoun-
tered, despite a lack of retrieval of contextual details associ-
ated with the encoding episode. The existence of two distinct
processes involved in recognition has received a substantial
amount of empirical support (see Yonelinas 2002 for a re-
view [9]).
Human lesion studies reveal impairment in familiarity
following EC/PC lesions [7,10]. In contrast, hippocampal
lesions lead to impairment in recollection with
preservation of familiarity [7]. These studies highlight a
functional double dissociation between the hippocampus
and EC/PC region, the latter being associated with familiar-
ity. This was further corroborated by functional magnetic
resonance imaging (fMRI) studies showing that activation
in the EC/PC was associated with familiarity-based recogni-
tion but not with recollection [8,11]. Taken together, these
results support the involvement of the EC/PC region in
familiarity-based recognition.
Recent articles have reviewed the literature looking at fa-
miliarity and recollection in aging individuals with normal
cognition, mild cognitive impairment (MCI), and AD
[12,13]. Overall, these reviews suggest that, although
recollection is impaired in the course of normal aging,
familiarity is preserved [12]. The presence of familiarity def-
icits inMCI andADpatients is not corroborated by all studies.
However, the results of these reviews indicate that familiarity
deficits tend to be present inMCI individuals at increased risk
of AD. Looking at familiarity performance in cognitively
normal individuals at increased risk ofADcould help defining
whether the presence of familiarity deficits represents an early
cognitive marker for the development of AD.
The apolipoprotein E (APOE) gene is involved in regu-
lating metabolism and the transportation of lipids, such as
cholesterol [14]. It is also involved in the growth and repairof neuronal and axonal membranes during development, and
following lesions [14]. The APOE locus contains two alleles
that are polymorphic and exist in three variants: ε2, ε3, and
ε4. The ε3 allele is the most common and found in 78% of
individuals [15]. The ε4 and ε2 alleles are far less common
and are represented in 15% and 7% of individuals, respec-
tively [15]. The ε4 allele of the APOE gene, the APOE ε4,
is a well-documented risk factor for both familial and spo-
radic AD [16]. The ε4 allele has widely been associated
with a higher risk and a younger age of onset of AD [17].
Furthermore, the risk related to the ε4 allele is “dose depen-
dant”: individuals with only one ε4 allele show a 2.8–4.4
times increased risk for AD, whereas individuals with two
ε4 alleles show a 7.0–19.3 times increased risk [16,18].
Consequently, cognitively intact aging individuals with
APOE ε4 are more likely to harbor neurofibrillary tangles
at the transentorhinal level than noncarriers. Accordingly,
a study showed a volume reduction in the medial temporal
lobe of nondemented aging individuals, APOE ε4 carriers
[19].
The objective of this study was to investigate the perfor-
mance in familiarity of aging individuals carrying an
APOE ε4 allele and compare it with aging individuals who
are noncarriers. Owing to an increased likelihood of
harboring AD neuropathology at a subclinical stage, we hy-
pothesized that nondemented individuals with APOE ε4 will
show decreased performance in familiarity-based recogni-
tion.2. Methods
2.1. Participants
Older Caucasians adults aged between 55 and 80 years
were recruited via advertisements in community newspa-
pers. To be eligible for the study, participants had to meet
the following criteria: French or English as a first language;
absence of current or past neurologic, psychiatric, or severe
medical conditions; no current or past history of substance
abuse; no current medication known to cross the blood-
brain barrier or alter cognitive functioning; .10 years of
formal education; and geriatric depression scale [20] and
Beck anxiety inventory [21] scores within the normal range.
All data were collected as part of a larger fMRI study. The
Douglas Mental Health University Institute’s research ethics
board approved the protocol of the study, and all participants
provided informed written consent. Recruited participants
underwent a cognitive test battery to allow the exclusion
of individuals with suspected cognitive impairment, as
defined by a performance of.1.5 standard deviations lower
than age-adjusted mean. Participants were also asked to pro-
vide a saliva sample to determine their APOE genotype.
They were informed that results from this genetic test would
not be disclosed to them. A total of 88 older individuals
completed all testing procedures. Four participants were
removed from analyses because of suspected MCI. Three
D. Schoemaker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 132-139134other participants were removed from the analyses because
of a performance suggesting a lack of comprehension of
the instructions associated with the recollection and famil-
iarity task (as indicated by an absence of variance in re-
sponses). Thus, the final sample used in the analyses
included 81 older adults (male/female: 38/43).2.2. Cognitive evaluation
The tests administered in the cognitive evaluation
included (1) mini-mental status examination [22]; (2) Mon-
treal cognitive assessment [23]; (3) Rey auditory verbal
learning test [24]; (4) the copy and immediate recall
(3-minutes delay) of the Rey-Osterrieth complex figure
test [25]; (5) letter (FAS) and category fluency (animals)
[26]; (6) trail making tests A and B [27]; (7) digit symbol
substitution—90-seconds version [28]; (8) Boston naming
test—60 items [29]; (9) color naming, reading, and interfer-
ence conditions from the Stroop color-word test [30]; (7)
digit span subtest of the Wechsler adult intelligence scale
III [31]; and the matrix reasoning subtest of the Wechsler
abbreviated scale of intelligence II [32].2.3. Quantification of familiarity and recollection2.3.1. Stimuli
A total of 135 black and white neutral Caucasian faces
were selected from the FACES database [33] and were
divided into three lists of 45 faces. Each list was equated
for age and gender of the faces. The first and second lists
of faces were used as targets during the first and second en-
coding condition. Faces from the third list were used as dis-
tractors during the recognition.
2.3.2. Experimental paradigm
The paradigmof this experiment shows similaritywith the
process dissociation procedure (PDP) developed by Jacoby
in 1991 [34] as it is also based on the assumption that, if
the recognition of an item is based on recollection, partici-
pants should be able to provide contextual details associated
with the encoding of this item. Consistently with the PDP, the
encoding phase of our task consisted of two contextually
distinct encoding conditions. However, in opposition to the
PDP, it estimates recollection and familiarity from a unique
recognition phase. This procedure has the advantages of be-
ing simpler to understand, faster to complete, and to avoid
methodological biases associated with different response
biases that can come with different conditions.
2.3.3. Encoding
The encoding phase was divided into two distinguishable
conditions: the “blue” and “red” encoding conditions. In
each encoding condition, participants were presented with
45 faces in a randomized order, for a total of 90 faces. Faces
were presented for 4 seconds with a 250-milliseconds inter-val. In the “blue” condition, faces were displayed on the
right side of the screen, on a blue background, and, for
each face, participants were asked to answer the question
“Does this person looks trustworthy?” In the “red” condi-
tion, faces were presented on the left side, on a red back-
ground, and, for each face, participants were asked to
answer the question “Does this person looks friendly?”
These encoding questions were meant to favor a deeper en-
coding of the faces and provide additional anchors for recol-
lection at the time of the recognition. Participants received
the instructions pertaining the upcoming encoding condi-
tions before the beginning of each condition. The order of
presentation of the encoding conditions was counterbal-
anced across subjects. The encoding procedure is illustrated
in Fig. 1A.
2.3.4. Recognition
After the encoding phase, participants received instruc-
tions pertaining the upcoming recognition procedure. The
recognition procedure was self-paced. Participants were pre-
sented with all faces presented during the encoding phase as
well as new unseen faces (distractors). Faces were presented
one at a time in the center of the screen on a gray background.
For each presented face, participants were first asked to
define whether this face was “old” (presented during the en-
coding phase, in either condition) or “new” (not seen before).
Second, if participants recognized the face as being “old,”
they were then asked whether this face was presented in the
“red” or the “blue” encoding condition. To avoid biases asso-
ciated with guesses, participants were given the option to
answer “can’t remember” when they couldn’t remember in
which condition the face was presented. Participants were
given three practice trials (two target faces and ne distractor,
same for all participants) before starting the recognition. Af-
ter completing the practice trials, participants saw the re-
maining 88 target and 44 distractor faces in random order.
The recognition procedure is illustrated in Fig. 1B.
2.3.5. Quantification of responses
The hit rate was computed using the number of target
faces correctly recognized as “old” divided by the total num-
ber of targets. The recollection rate was computed using the
number of target faces correctly recognized as “old” and
classified in the correct encoding condition, divided by the
total number of targets. The familiarity rate was computed
using the number of target faces correctly recognized as
“old” but with a failure to provide a correct classification
of the encoding condition, divided by the total number of tar-
gets. False alarm rate was computed using the number of
“new” faces falsely identified as being “old” divided by
the total number of distractors.2.4. APOE genotyping
Saliva samples were collected using Norgen Biotek Corp.
Saliva DNA Collection, Preservation and Isolation kits
Fig. 1. Experimental paradigm. Schematic representation of the procedure and events in the experimental paradigm. The encoding task consisted in the “blue”
(A-i) and the “red” (A-ii) encoding condition. Forty-five Caucasian faces were presented in random order in each condition. Faces were presented on the screen
for 4 seconds (s) with a 250-milliseconds (ms) interval. The recognition (B) was self-paced and consisted of a two-step procedure. Participants were presented
with the 90 targets from the encoding phase as well as 45 new faces (distractors). First, participants were asked to determine whether the face presented was
“old” or “new.” If the face was judged to be “old,” participants were then asked to determine in which encoding condition it was presented.
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the DNAwas performed according to manufacturer specifi-
cations. The genotyping technique used for APOE polymor-
phism has been described previously [35]. Participants with
one or more ε4 allele were classified as APOE ε4 positive
and participants not presenting an ε4 allele as APOE ε4
negative. The distribution of APOE genotypes in our sample
is consistent with previously published reports [36] and is
presented in Table 1.Table 1
APOE genotypes distribution in the studied sample
APOE genotype n % of sample
ε2-ε3 4 4.94
ε3-ε3 55 69.14
ε2-ε4 1 1.23
ε3-ε4 20 24.69
Total 80 100
Abbreviation: APOE, apolipoprotein.2.5. Statistical analysis
Analyses were performed using the Statistical Package
for the Social Sciences (SPSS; IBM, Chicago, USA) version
20. Differences between APOE ε4 negative and APOE ε4
positive groups on demographic variables and cognitive
measures were analyzed using independent samples t tests.
The assumption of equal variance was verified using Lev-
ene’s test. A c2 test was used to assess the difference in
the male/(female 1 male) ratio between groups.
The performance of the two groups on hit, recollection,
familiarity, and false alarm rates obtained in the recollection
and familiarity task was contrasted using independent sam-
ples t tests and Levene’s test for equality of variances. To
correct for multiple comparisons, the alpha for statistical sig-
nificance was adjusted to P, .01 to account for the four per-
formed comparisons, as per the Bonferroni procedure.
A one-way analysis of covariance was also computed to
compare performances of both groups on the task, while
controlling for age, gender, and education.
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3.1. Demographic and cognitive characteristics of study
subjects
Demographic characteristics and results on cognitive tests
are summarized for each group separately in Table 2.
APOE ε4 negative and positive groups did not significantly
differ in terms of age and years of education. The c2 test
did not show any significant association between the APOE
ε4 status and gender c2 (1, n5 81)5 1.19, P. .05, suggest-
ing that both groups did not significantly differ in terms of
gender representation. When contrasting scores of the two
groups on standard cognitive tests, only one comparison
reached statistical significance, suggesting a higher perfor-
mance on the immediate recall of the Rey-Osterrieth com-
plex figure test for the APOE ε4 positive group. However,
this result did not survive statistical correction for multiple
comparisons.3.2. Familiarity and recollection as a function ofAPOE ε4
status
When contrasting the performance of APOE ε4 positive
and negative groups on our recollection and familiarityTable 2
Summary of demographic variables and cognitive performance on standard cogni
Demographics and cognitive
performance
APOE ε4 negative
Mean (SD), n 5 60
Age 65.15 (6.46)
Education 14.88 (2.54)
Male/(male 1 female) 0.43
MMSE 29.31 (0.88)
MoCA 27.47 (2.43)
RAVLT
Total learning 53.19 (8.80)
Recall after interference 11.19 (3.06)
Delayed recall 11.17 (3.36)
Recognition 14.69 (0.70)
Rey-Osterrieth complex figure
Copy 30.90 (3.30)
Immediate recall 17.23 (5.53)
Letter fluency (FAS) 42.62 (12.35)
Category fluency (animals) 20.84 (5.28)
Digit symbol substitution test 44.23 (10.21)
Trail making test
A (letter) 32.15 (11.13)
B (letter-number) 73.07 (29.00)
Stroop color-word interference test
Color naming 30.36 (4.76)
Word reading 23.37 (5.90)
Inhibition 60.51 (14.29)
Digit span
Total forward 6.66 (1.38)
Total backward 5.36 (1.26)
Boston naming test 54.17 (4.80)
Matrix reasoning 19.28 (4.53)
Abbreviations: APOE, apolipoprotein; SD, standard deviation; MMSE, mini-me
auditory verbal learning test.
NOTE. All comparisons for continuous variables have been computed using ind
groups. The asterisk shows a significant between-group difference with P , .05.task, the only significant difference was found in the famil-
iarity rate. More precisely, the familiarity rate was signifi-
cantly reduced in the APOE ε4 positive group
t(1,79) 5 2.79, P 5 .007. The hit rate t(1,79) 5 1.31, NS,
recollection rate t(1,79) 5 20.79, NS, and false alarm rate
t(1,79) 5 1.46, NS did not differ significantly between the
groups. These results are summarized in Table 3 and the dif-
ference in familiarity between groups is illustrated in Fig. 2.
The effect of APOE ε4 status on familiarity was still sig-
nificant after controlling for age, gender, and education of
participants F (1, 76)5 8.74, P5 .004, whereas it remained
nonsignificant for hit rate F (1, 76)5 2.60, NS, recollection
rate F (1, 76) 5 0.37, NS, and false alarm rate F (1,
76) 5 1.54, NS.4. Discussion
In this article, we investigated the effects of APOE ε4 sta-
tus on familiarity in a sample of cognitively normal aging in-
dividuals. Our results highlight a significant reduction in
familiarity in aging individuals who are carriers of the
APOE ε4 allele, relative to noncarriers. Familiarity was the
only cognitive domain that was significantly reduced in
this group. Furthermore, our analysis demonstrated thattive tests
APOE ε4 positive
Mean (SD), n 5 21
Between-group
comparison
63.48 (6.22) t 5 1.03 (NS)
15.29 (2.08) t 5 20.65 (NS)
0.57 c2 5 1.19 (NS)
29.33 (0.73) t 5 20.13 (NS)
27.14 (2.15) t 5 0.53 (NS)
50.33 (12.00) t 5 1.15 (NS)
10.24 (3.99) t 5 1.12 (NS)
10.43 (3.83) t 5 0.84 (NS)
14.42 (1.36) t 5 0.86 (NS)
31.52 (3.40) t 5 20.74 (NS)
20.21 (4.86) t 5 22.13 (P 5 .04*)
40.62 (10.89) t 5 0.66 (NS)
19.57 (3.43) t 5 1.03 (NS)
45.67 (11.06) t 5 20.54 (NS)
31.76 (10.50) t 5 0.14 (NS)
75.43 (31.48) t 5 20.31 (NS)
32.29 (5.83) t 5 21.50 (NS)
23.76 (5.72) t 5 20.26 (NS)
63.43 (12.96) t 5 20.82 (NS)
6.71 (1.19) t 5 20.16 (NS)
5.24 (1.37) t 5 0.36 (NS)
53.90 (4.00) t 5 0.23 (NS)
19.05 (4.35) t 5 0.16 (NS)
ntal state examination; MoCA, Montreal cognitive assessment; RAVLT, Rey
ependent sample t tests. A c2 test was used to compare gender ratio between
NS indicates absence of between-group significance.
Table 3
Performance on the recollection and familiarity task as a function of APOE
ε4 status
Recollection and
familiarity task
APOE ε4 negative
Mean (SD)
APOE ε4 positive
Mean (SD)
Hit rate 0.61 (0.14) 0.56 (0.14)
Recollection rate 0.24 (0.10) 0.26 (0.11)
Familiarity rate 0.37 (0.10) 0.30 (0.07)**
False alarm rate 0.30 (0.11) 0.25 (0.12)
Abbreviations: APOE, apolipoprotein; SD, standard deviation; ANOVA,
analysis of variance.
All between-group comparisons have been computed using a one-way
ANOVA. Double asterisks show a significant group difference with a
P , .01.
D. Schoemaker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 132-139 137this effect was not due to differences in age, education, or
gender between groups.
Consistently with previous studies, we failed to find
impairment in performance on standard cognitive tests in
the APOE ε4 positive group [37,38]. The APOE ε4
positive group even outperformed the APOE ε4 negative
group on the immediate recall of the Rey-Osterrieth complex
figure [25]. Because no other cognitive impairment was
found in the APOE ε4 positive group, this suggests that fa-
miliarity is more sensitive to the effects of APOE ε4 than
other cognitive measures administered. This also suggests
that the effects of APOE ε4 on cognition might occur
much before the onset of overt dementia. Individuals car-
rying the APOE ε4 are at an increased risk of AD compared
with noncarriers [39,40]. As a consequence, a greater
frequency of individuals with neuropathologic alteration
associated with AD is expected in this population.
Familiarity has previously been linked to the integrity ofFig. 2. Familiarity performance as a function of APOE ε4 status. Individual
performances in familiarity plotted separately for APOE ε4 negative and
APOE ε4 positive groups. **Significant with P , .01.EC/PC regions [7,10]. Therefore, the specific impairment
in familiarity observed in the group of ε4 carriers might
reflect very early cognitive changes occurring as a
consequence of neurofibrillary accumulation in these brain
regions. Future studies should, thus, aim to investigate
neuroanatomic and/or functional correlates of this
impairment.
An overlap in the performance in familiarity between
both groups is observed in the plot illustrating the results.
Although it is rare that APOE ε4 carriers reach a high level
of performance in familiarity, multiple noncarriers show a
performance that is in the lower range. This overlap is ex-
pected and consistent with our hypothesis. We hypothesize
that impairment familiarity is a marker for early neuropath-
ologic alterations associated with subclinical AD. APOE ε4
is a well-documented and important risk factor for the devel-
opment of AD, but it remains a risk factor only. Thus, many
individuals with APOE ε4 will never develop AD over time.
On the other hand, nondemented aging individuals without
APOE ε4 can also have subclinical AD and harbor AD
neuropathology at the transentorhinal stage. Consequently,
as represented in our results, it is expected that some ε4 car-
riers show a normal performance in familiarity and that some
noncarriers perform in a deficient manner. Here, longitudinal
studies are necessary to define whether a low performance in
familiarity is predictive of future cognitive decline and de-
mentia.
Growing evidence indicates that the ε4 allele put women
at increased risk of cognitive decline compared with men
[14,41]. Although causes behind this gender dimorphism
are still a matter of debate, gender remains an important
factor to take into consideration when investigating the
effects of APOE ε4. In this study, both groups had an
equivalent gender distribution. Furthermore, including
gender as a covariate in a statistical model did not alter the
significance of our findings. This suggests that our results
were not explained by gender difference between groups.
To our knowledge, only one article has previously looked
at the effect of APOE ε4 on familiarity [42]. As part of their
study, Tse et al. used a memory exclusion paradigm that al-
lows evaluating the ability to correctly reject familiar infor-
mation that is contextually irrelevant to the demand of the
task. As it directly opposes automatic and controlled recog-
nition processes, this procedure is believed to also rely on
executive control. Overall, results from the Tse et al. article
highlight an increased reliance on familiarity and a reduced
ability to control familiarity-based information in nonde-
mented aging individuals with APOE ε4. It is important to
note that in their article, although APOE ε4 carriers were
judged cognitively normal, they showed poorer performance
in a free recall and computational span test than the noncar-
riers, suggesting some a-priori differences in cognitive func-
tioning between groups. The authors hypothesized that
changes in mechanisms of attentional control might be
responsible for the observed difference between groups.
Although this article demonstrates some changes in the
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carriers, the used paradigm is different than the one used
in the present article and does not provide a separate estimate
of familiarity and recollection. It is, therefore, difficult to
compare the results of Tse et al. to the findings obtained in
the present study.
Although we did not find any evidence for other forms of
cognitive impairment in the group of ε4 carriers, the pres-
ence of deficits in executive function and spatial attention
has previously been shown in this population [43,44]. It is
possible that a more detailed cognitive evaluation would
have exposed differences between the cognitive profile of
APOE ε4 positive and negative groups. Accordingly, by
using a specific visual cueing paradigm, Greenwood et al.
[44] found evidence for reduced visual discrimination accu-
racy and visuospatial attention in nondemented individuals
with one or two APOE ε4 alleles. Because the present recol-
lection and familiarity task involves a spatial component
(left vs. right side presentation), the experimental paradigm
perhaps contributed to the observed familiarity deficits.
Furthermore, past studies have demonstrated that perfor-
mance in recollection and familiarity might be influenced
by the stimulus modality [45–47]. For example, Embree
et al. [46] showed that, although the stimulus type did not in-
fluence recollection, familiarity for words, but not for pic-
tures, was impaired in MCI individuals. Previous articles
have highlighted a possible hemispheric asymmetry in vol-
ume loss occurring over the course of AD [48,49].
Because of the known hemispheric specialization for
verbal functions, the replication of these findings using
verbal instead of nonverbal material could provide
interesting additional information related to familiarity and
recollection performance in populations at risk of AD.
Thus, future studies should aim to replicate the current
findings using different experimental paradigms and
different type of stimulus.
Memory evaluation is a central component of clinical
investigation associated with the differential diagnosis of
cognitive complains occurring in aging individuals. Here,
we highlighted familiarity impairment in aging individuals
at increased risk of AD, in the absence of any other observ-
able cognitive deficits. Although the scope of this study is
limited by the small sample of APOE ε4 positive individuals,
the results of this article suggest that familiarity deficits
might arise before other cognitive manifestations associated
with beginning AD. Thus, the inclusion of a task evaluating
familiarity in clinical evaluation might allow an earlier iden-
tification of individuals with subclinical AD. However, more
research is needed to confirm the relevance of familiarity
assessment in clinical settings.Acknowledgments
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1. Systematic review: Relevant articles were identified
via a search through online databases PubMed and
PsycINFO with the use of the keywords “familiar-
ity,” “recollection,” “recognition,” and “apolipopro-
tein E.” The abstract of every article retrieved from
this search was reviewed. Pertinent articles are cited
and discussed in the article.
2. Interpretation: Our results suggest that performance
in familiarity could represent an early cognitive
marker for individuals at risk of Alzheimer’s disease.
3. Future directions: The article proposes multiple di-
rections to further assess the predictive value of fa-
miliarity in the early detection of dementia. One of
the most important aspects addressed in the article
is the need for longitudinal studies to define whether
baseline measures in familiarity can accurately pre-
dict cognitive deterioration over time. Furthermore,
future research should aim to achieve a better under-
standing of the neuroanatomic basis of this differen-
tial impairment.References
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